摘要
目的探讨趋化因子5(CXCL5)在喉鳞状细胞癌(鳞癌)中的表达水平及其与临床分期、分化程度、淋巴转移及预后等临床病理参数的关系。方法用免疫组化法检测CXCL5蛋白在95例喉鳞癌组织和36例声带息肉(对照组)组织中的表达,分析其与临床病理学特征的关系。KaPlan-Meier法与Log-rank检验分析生存情况。结果CXCL5蛋白在喉鳞癌组和对照组的阳性高表达率分别为61.1%和19.4%(P<0.05),其表达分别在不同的临床分期、T分期及淋巴转移之间差异有统计学意义(P值均<0.05),而在性别、年龄、吸烟、分化程度及分型之间差异无统计学意义(P值均>0.05);单因素分析结果显示喉癌患者CXCL5蛋白高表达组比CXCL5低表达组的生存时间更短,临床分期、T分期、淋巴结是否转移、分化程度对生存时间的影响有统计学意义(P值均<0.05),而年龄、性别、吸烟与患者的预后无关(P值均>0.05)。结论 CXCL5蛋白高表达可能是影响喉鳞癌预后的重要因素。CXCL5蛋白可能是肿瘤生物轴重要的靶点,为喉癌早期浸润的诊断和治疗提供新的实验依据。
Objective To investigate the expression of chemokine receptor（CXCLS） in laryngeal squanlous cell carcinoma（LSCC） and its relationship with the clinicopathologic features, such as clinical stage and lymph node metastasis. Methods The expression of CXCL5 was detected by immunohistochemistry in LSCC tissues of 95 cases and benign le- sions of 36 cases （control）. The correlation of CXCL5 expression with various clinicopathologic features was evaluated with the single factor analysis. Results The expression levels of CXCL5 in LSCC and control were 61.1% and 19.4% （P 〈 0.05）. The clinicopathological analysis showed that CXCL5 level had a relationship with the clinical stage, T stage, and lymph node metastasis （ P 〈 0.05 ）, but not with gender, age, smoking and differentiation （ P 〉 0.05 ）. Survival analysis showed that the patients with high CXCL5 expression had significantly poorer outcome as compared with the patients with low CXCI_5 expression. The survival was related to clinical stage ,T stage ,lymph node metastasis, and differentiation（P 〈 0.05 ）, but not with age, sex, and smoking（ P 〉 0.05 ）. Conclusion The expression of CXCL5 is significantly increased in LSCC ,which might be an important factor affecting the prognosis of LSCC. CXCL5 may be served as a new candidate molecular marker and therapeutic target of LSCC.
出处
《中华全科医学》
2015年第11期1754-1756,F0003,共4页
Chinese Journal of General Practice
基金
浙江省自然科学基金(Y2100578)
杭州市科技发展基金(20110833B09)
关键词
趋化因子
趋化因子5
喉肿瘤
鳞状细胞癌
预后
Chemokine receptor
Chemokine receptor 5
Laryngeal neoplasms
Squamous cell carcinoma
Prognosis
